1159 related articles for article (PubMed ID: 32436994)
41. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?
Liu B; Li M; Zhou Z; Guan X; Xiang Y
J Autoimmun; 2020 Jul; 111():102452. PubMed ID: 32291137
[TBL] [Abstract][Full Text] [Related]
42. Tocilizumab challenge: A series of cytokine storm therapy experiences in hospitalized COVID-19 pneumonia patients.
Borku Uysal B; Ikitimur H; Yavuzer S; Ikitimur B; Uysal H; Islamoglu MS; Ozcan E; Aktepe E; Yavuzer H; Cengiz M
J Med Virol; 2020 Nov; 92(11):2648-2656. PubMed ID: 32484930
[TBL] [Abstract][Full Text] [Related]
43. Potential Role of Anti-interleukin (IL)-6 Drugs in the Treatment of COVID-19: Rationale, Clinical Evidence and Risks.
Crisafulli S; Isgrò V; La Corte L; Atzeni F; Trifirò G
BioDrugs; 2020 Aug; 34(4):415-422. PubMed ID: 32557214
[TBL] [Abstract][Full Text] [Related]
44. Tocilizumab use in patients with moderate to severe COVID-19: A retrospective cohort study.
Chilimuri S; Sun H; Alemam A; Kang KS; Lao P; Mantri N; Schiller L; Sharabun M; Shehi E; Tejada J; Yugay A; Nayudu SK
J Clin Pharm Ther; 2021 Apr; 46(2):440-446. PubMed ID: 33098139
[TBL] [Abstract][Full Text] [Related]
45. TOCIVID-19 - A multicenter study on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia. Study protocol.
Piccirillo MC; Ascierto P; Atripaldi L; Cascella M; Costantini M; Dolci G; Facciolongo N; Fraganza F; Marata A; Massari M; Montesarchio V; Mussini C; Negri EA; Parrella R; Popoli P; Botti G; Arenare L; Chiodini P; Gallo C; Salvarani C; Perrone F
Contemp Clin Trials; 2020 Nov; 98():106165. PubMed ID: 33031955
[TBL] [Abstract][Full Text] [Related]
46. Preemptive interleukin-6 blockade in patients with COVID-19.
Guillén L; Padilla S; Fernández M; Agulló V; García JA; Telenti G; García-Abellán J; Botella Á; Gutiérrez F; Masiá M
Sci Rep; 2020 Oct; 10(1):16826. PubMed ID: 33033405
[TBL] [Abstract][Full Text] [Related]
47. The role of tocilizumab therapy in critically ill patients with severe acute respiratory syndrome coronavirus 2.
Saffo Z; Guo W; Springer K; Maksimowicz-McKinnon K; Kak V; McKinnon JE; Bhargava P
J Osteopath Med; 2021 Jul; 121(8):705-714. PubMed ID: 34237804
[TBL] [Abstract][Full Text] [Related]
48. COVIDOSE: A Phase II Clinical Trial of Low-Dose Tocilizumab in the Treatment of Noncritical COVID-19 Pneumonia.
Strohbehn GW; Heiss BL; Rouhani SJ; Trujillo JA; Yu J; Kacew AJ; Higgs EF; Bloodworth JC; Cabanov A; Wright RC; Koziol AK; Weiss A; Danahey K; Karrison TG; Edens CC; Bauer Ventura I; Pettit NN; Patel BK; Pisano J; Strek ME; Gajewski TF; Ratain MJ; Reid PD
Clin Pharmacol Ther; 2021 Mar; 109(3):688-696. PubMed ID: 33210302
[TBL] [Abstract][Full Text] [Related]
49. Tocilizumab therapy for severely-ill COVID-19 pneumonia patients: a single-centre retrospective study.
Iqtadar S; Khan A; Mumtaz SU; Pascual-Figal DA; Livingstone S; Abaidullah S
J Physiol Pharmacol; 2022 Aug; 73(4):. PubMed ID: 36696245
[TBL] [Abstract][Full Text] [Related]
50. Case report: use of lenzilumab and tocilizumab for the treatment of coronavirus disease 2019.
Melody M; Nelson J; Hastings J; Propst J; Smerina M; Mendez J; Guru P
Immunotherapy; 2020 Oct; 12(15):1121-1126. PubMed ID: 32546029
[No Abstract] [Full Text] [Related]
51. IL-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome.
Kang S; Tanaka T; Inoue H; Ono C; Hashimoto S; Kioi Y; Matsumoto H; Matsuura H; Matsubara T; Shimizu K; Ogura H; Matsuura Y; Kishimoto T
Proc Natl Acad Sci U S A; 2020 Sep; 117(36):22351-22356. PubMed ID: 32826331
[TBL] [Abstract][Full Text] [Related]
52. Pulmonary vascular improvement in severe COVID-19 patients treated with tocilizumab.
Salvati L; Occhipinti M; Gori L; Ciani L; Mazzoni A; Maggi L; Capone M; Parronchi P; Liotta F; Miele V; Annunziato F; Lavorini F; Cosmi L
Immunol Lett; 2020 Dec; 228():122-128. PubMed ID: 33161002
[TBL] [Abstract][Full Text] [Related]
53. The Role of Inflammatory Cytokines (Interleukin-1 and Interleukin-6) as a Potential Biomarker in the Different Stages of COVID-19 (Mild, Severe, and Critical).
Ghofrani Nezhad M; Jami G; Kooshkaki O; Chamani S; Naghizadeh A
J Interferon Cytokine Res; 2023 Apr; 43(4):147-163. PubMed ID: 37062817
[TBL] [Abstract][Full Text] [Related]
54. The role of IL-6 and IL-6 blockade in COVID-19.
Potere N; Batticciotto A; Vecchié A; Porreca E; Cappelli A; Abbate A; Dentali F; Bonaventura A
Expert Rev Clin Immunol; 2021 Jun; 17(6):601-618. PubMed ID: 33874829
[TBL] [Abstract][Full Text] [Related]
55. Assessment of Tocilizumab (Humanized Monoclonal Antibody) for Therapeutic Efficacy and Clinical Safety in Patients with Coronavirus Disease (COVID-19).
Ullah S; Abid R; Haider S; Khuda F; Albadrani GM; Abdulhakim JA; Altyar AE; Abdel-Daim MM; Halimi SMA; Khalil AAK
Medicina (Kaunas); 2022 Aug; 58(8):. PubMed ID: 36013543
[TBL] [Abstract][Full Text] [Related]
56. Experience of using tocilizumab for treatment in Indonesian patients with severe COVID-19.
Widysanto A; Kurniawan A; Lugito NPH; Yuniarti M; Gunawan C; Angela ; Wiryanto J; Levinna ; Pradhana TM
Cytokine; 2021 Feb; 138():155393. PubMed ID: 33333393
[TBL] [Abstract][Full Text] [Related]
57. Early use of tocilizumab in the prevention of adult respiratory failure in SARS-CoV-2 infections and the utilization of interleukin-6 levels in the management.
Antony SJ; Davis MA; Davis MG; Almaghlouth NK; Guevara R; Omar F; Del Rey F; Hassan A; Arian MU; Antony N; Prakash BV
J Med Virol; 2021 Jan; 93(1):491-498. PubMed ID: 32644254
[TBL] [Abstract][Full Text] [Related]
58. Tocilizumab demonstrates superiority in decreasing C-reactive protein levels in hospitalized COVID-19 patients, compared to standard care treatment alone.
Calderón-Ochoa C; Plamenov-Donchev N; Hernández-Quiñones F; Mendoza-López O; Hinojos-Gallardo LC; Longino-Gómez AJ; Hernádez-Saldaña R; Duque-Rodríguez J; Ishida-Gutiérrez MC
Microbiol Spectr; 2024 Jun; 12(6):e0249823. PubMed ID: 38687065
[TBL] [Abstract][Full Text] [Related]
59. Editorial: Tocilizumab, a Humanized Therapeutic IL-6 Receptor (IL-6R) Monoclonal Antibody, and Future Combination Therapies for Severe COVID-19.
Parums DV
Med Sci Monit; 2021 Jul; 27():e933973. PubMed ID: 34276042
[TBL] [Abstract][Full Text] [Related]
60. Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation.
Della-Torre E; Lanzillotta M; Campochiaro C; Cavalli G; De Luca G; Tomelleri A; Boffini N; De Lorenzo R; Ruggeri A; Rovere-Querini P; Castagna A; Landoni G; Tresoldi M; Ciceri F; Zangrillo A; Dagna L
Front Immunol; 2021; 12():675678. PubMed ID: 33995419
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
